ATE222496T1 - Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen - Google Patents

Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen

Info

Publication number
ATE222496T1
ATE222496T1 AT97920756T AT97920756T ATE222496T1 AT E222496 T1 ATE222496 T1 AT E222496T1 AT 97920756 T AT97920756 T AT 97920756T AT 97920756 T AT97920756 T AT 97920756T AT E222496 T1 ATE222496 T1 AT E222496T1
Authority
AT
Austria
Prior art keywords
levulose
cell death
related diseases
association
acetylcystone
Prior art date
Application number
AT97920756T
Other languages
English (en)
Inventor
Antonio Esteras
Leonida Bruseguini
Jose Maria Estrela
Original Assignee
Zambon S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon S A filed Critical Zambon S A
Application granted granted Critical
Publication of ATE222496T1 publication Critical patent/ATE222496T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97920756T 1996-05-16 1997-05-13 Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen ATE222496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES09601091A ES2114817B1 (es) 1996-05-16 1996-05-16 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.
PCT/ES1997/000122 WO1997042961A1 (es) 1996-05-16 1997-05-13 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas

Publications (1)

Publication Number Publication Date
ATE222496T1 true ATE222496T1 (de) 2002-09-15

Family

ID=8294833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920756T ATE222496T1 (de) 1996-05-16 1997-05-13 Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen

Country Status (7)

Country Link
EP (1) EP0839534B1 (de)
AT (1) ATE222496T1 (de)
DE (1) DE69714821T2 (de)
DK (1) DK0839534T3 (de)
ES (1) ES2114817B1 (de)
PT (1) PT839534E (de)
WO (1) WO1997042961A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819616A1 (de) * 1998-05-04 1999-11-11 Hexal Ag Verwendung von Antioxidantien zur Behandlung von entzündlichen Hauterkrankungen
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
FR2815042B1 (fr) * 2000-10-06 2005-01-07 Haguenauer Odile Cohen Utilisation d'une composition a activite antioxydante pour le conditionnement de cellules souches

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
IT1217445B (it) * 1988-04-29 1990-03-22 Altergon Sa Composizione farmaceutiche orosolubili contenti acetilcisteina
DE4134723C1 (de) * 1991-10-21 1993-02-11 Pfrimmer Kabi Gmbh & Co Kg, 8520 Erlangen, De
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making

Also Published As

Publication number Publication date
DK0839534T3 (da) 2002-12-23
WO1997042961A1 (es) 1997-11-20
ES2114817A1 (es) 1998-06-01
DE69714821D1 (de) 2002-09-26
EP0839534B1 (de) 2002-08-21
EP0839534A1 (de) 1998-05-06
ES2114817B1 (es) 1999-02-16
PT839534E (pt) 2002-12-31
DE69714821T2 (de) 2003-04-10

Similar Documents

Publication Publication Date Title
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
BR9607846A (pt) Inibição da associação de tau-tau
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2176285T3 (es) Amidas y esteres de peptidos inhibidoras del cancer de seres humanos.
GB0005251D0 (en) Therapeutic compounds
AU8692391A (en) Improvements in or relating to organic compounds
DE69430440D1 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
ATE338062T1 (de) Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen
ATE164064T1 (de) Zusammensetzungen, die mono oder polyhydroxylierte aminosäuren zur behandlung des insulinunabhängigen diabetes mellitus enthalten
ATE224714T1 (de) Behandlung von tinnitus mit neuroprotektiven wirkstoffen
BR9911060A (pt) Composições compreendendo mono- ou dinitrato orgânico para tratar impotência
ATE218320T1 (de) Kombinationen von vasoaktiven stoffen mit fettsäuren zur verhütung von haarausfall
DE69412049D1 (de) Hemmung von dysfunctionalen Uterusblutungen
DE69501105D1 (de) L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
ATE321067T1 (de) Neuartige peptidderivate mit thiazolyl-alanin- resten
ATE222496T1 (de) Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen
ATE168988T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
GB0016052D0 (en) Ruthenium (II) compounds
DE689838T1 (de) Verwendung von Diademosim 5',5'''-p1,p4-Tetraphosphat zur Behandlung von ischämischen Myokard-Erkrankungen
GR3022471T3 (en) Novel cardioprotective agents.
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
DE69909395D1 (de) Zusammensetzung mit ketanserin und carnitin zur behandlung von crps
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0839534

Country of ref document: EP

REN Ceased due to non-payment of the annual fee